These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 17584139)

  • 41. Neurobiology of cholecystokinin.
    Moran TH; Schwartz GJ
    Crit Rev Neurobiol; 1994; 9(1):1-28. PubMed ID: 8828002
    [TBL] [Abstract][Full Text] [Related]  

  • 42. CCK antagonists: pharmacology and therapeutic interest.
    Wettstein JG; Buéno L; Junien JL
    Pharmacol Ther; 1994; 62(3):267-82. PubMed ID: 7972336
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.
    Hruby VJ; Agnes RS; Davis P; Ma SW; Lee YS; Vanderah TW; Lai J; Porreca F
    Life Sci; 2003 Jun; 73(6):699-704. PubMed ID: 12801591
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide.
    Slaninova J; Knapp RJ; Wu JJ; Fang SN; Kramer T; Burks TF; Hruby VJ; Yamamura HI
    Eur J Pharmacol; 1991 Jul; 200(1):195-8. PubMed ID: 1663041
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholecystokinin-A receptor ligands based on the kappa-opioid agonist tifluadom.
    Bock MG; DiPardo RM; Evans BE; Rittle KE; Whitter WL; Veber DF; Freidinger RM; Chang RS; Chen TB; Lotti VJ
    J Med Chem; 1990 Jan; 33(1):450-5. PubMed ID: 2153212
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Functional comparisons of gastrin/cholecystokinin receptors in isolated preparations of gastric mucosa and ileum.
    Patel M; Spraggs CF
    Br J Pharmacol; 1992 Jun; 106(2):275-82. PubMed ID: 1393262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estrogen and CCK1 receptor modification of mu-opioid receptor binding in the cortex of female rats.
    Quesada A; Micevych P
    Brain Res; 2006 Feb; 1073-1074():316-20. PubMed ID: 16472782
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vivo binding affinities of cholecystokinin agonists and antagonists determined using the selective CCKB agonist [3H]pBC 264.
    Durieux C; Ruiz-Gayo M; Roques BP
    Eur J Pharmacol; 1991 Dec; 209(3):185-93. PubMed ID: 1797561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cholecystokinin and gastrin are not equally sensitive to GTP gamma S at CCKB receptors: importance of the sulphated tyrosine.
    Lallement JC; Oiry C; Lima-Leite AC; Lignon MF; Fulcrand P; Galleyrand JC; Martinez J
    Eur J Pharmacol; 1995 Jul; 290(2):61-7. PubMed ID: 8575534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cholecystokinin dipeptoid antagonists: design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists.
    Boden PR; Higginbottom M; Hill DR; Horwell DC; Hughes J; Rees DC; Roberts E; Singh L; Suman-Chauhan N; Woodruff GN
    J Med Chem; 1993 Mar; 36(5):552-65. PubMed ID: 7684452
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Are radioligand antagonist/agonist binding ratios in rat pancreas predictive of functional efficacy of cholecystokinin receptor agonists and antagonists?
    Patel S; Chapman KL; Smith AJ; Bailey I; Freedman SB
    Regul Pept; 1996 Aug; 65(1):29-35. PubMed ID: 8876033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Conformational analysis of possible biologically active (receptor-bound) conformations of peptides derived from cholecystokinin, cerulein and little gastrin and the opiate peptide, Met-enkephalin.
    Pincus MR; Murphy RB; Carty RP; Chen J; Shah D; Scheraga HA
    Peptides; 1988; 9 Suppl 1():145-52. PubMed ID: 2856638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
    Nikiforovich GV; Kolodziej SA; Nock B; Bernad N; Martinez J; Marshall GR
    Biopolymers; 1995 Oct; 36(4):439-52. PubMed ID: 7578939
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis).
    Oliver AS; Vigna SR
    Gen Comp Endocrinol; 1997 Jan; 105(1):91-101. PubMed ID: 9000471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.
    Berna MJ; Jensen RT
    Curr Top Med Chem; 2007; 7(12):1211-31. PubMed ID: 17584143
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intermolecular interactions between peptidic and nonpeptidic agonists and the third extracellular loop of the cholecystokinin 1 receptor.
    Giragossian C; Sugg EE; Szewczyk JR; Mierke DF
    J Med Chem; 2003 Jul; 46(16):3476-82. PubMed ID: 12877585
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cholecystokinin-Mediated Neuromodulation of Anxiety and Schizophrenia: A "Dimmer-Switch" Hypothesis.
    Ballaz SJ; Bourin M
    Curr Neuropharmacol; 2021; 19(7):925-938. PubMed ID: 33185164
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cholecystokinins and their receptors. Functional aspects].
    Böhme GA; Blanchard JC
    Therapie; 1992 Nov; 47(6):541-8. PubMed ID: 1301646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.